Tag: University of Toronto

  • Brain Star Award Feature: Andrew Mocle, University of Toronto, won this prize based on the excellence of the research and its potential benefits to the health of Canadians. Brain Star Awards are presented by the Canadian Association for Neuroscience (CAN) and the Canadian Institutes of Health’s Institute of Neurosciences, Mental Health and Addiction

    The hippocampus is a critical brain region for encoding and recall of episodic memories. The physical trace left in the brain by memory formation is called an ‘engram’, and the process by which new engrams are formed is still unclear. In this work, Andrew Mocle, working in the laboratory of Sheena Josselyn, used advanced imaging techniques to track neurons and their patterns of activity before, during, and after memory encoding. The resulting data prompted a new engram formation model, whereby small ensembles of neurons (instead of individual cells) are allocated to an engram depending on their average excitability at the time of learning. The demonstration that highly-excitable ensembles are preferentially allocated to encode newly learned information represents a major conceptual advance in the study of how memories are stored in the brain.

    Read more: https://can-acn.org/brain-star-award-winner-andrew-mocle/

    Featured scientific publication: Mocle, Andrew J., Adam I. Ramsaran, Alexander D. Jacob, Asim J. Rashid, Alessandro Luchetti, Lina M. Tran, Blake A. Richards, Paul W. Frankland, and Sheena A. Josselyn. “Excitability Mediates Allocation of Pre-Configured Ensembles to a Hippocampal Engram Supporting Contextual Conditioned Threat in Mice.” Neuron 112, no. 9 (May 1, 2024): 1487-1497.e6.

    https://doi.org/10.1016/j.neuron.2024.02.007


  • From: SickKids news

    Scientists use a peptide to strengthen connections between brain cells and restore memory in a pre-clinical model.

    Research led at The Hospital for Sick Children (SickKids) is illuminating the mechanism underlying memory, which could result in future therapeutic targets for conditions such as Alzheimer’s disease and dementia. 

    Alzheimer’s disease is a condition that causes memory loss, characterized by the accumulation of a protein, called A-beta, in the brain that damages neurons and their connections.

    Published in Nature Neuroscience, Drs. Paul Frankland and Sheena Josselyn, Senior Scientists in the Neurosciences & Mental Health program, used a peptide to block adverse effects of the accumulation of A-beta in pre-clinical models – a technique that showed promise in restoring memory.

    (more…)

  • In a recent interview published in Best Health Canada magazine, Toronto brain surgeon Gelareh Zadeh discusses a new brain cancer therapy that could buy precious time for terminal patients.

    Working with a colleague at the Princess Margaret Cancer Centre, she developed a blood test that can not only detect brain cancer but reveal the type of tumour and its likelihood to recur. And in a recent, groundbreaking clinical trial at the UHN, she helped identify a new combination therapy that may give patients with glioblastoma months or even years longer to live. In the interview, Zadeh discusses neurosurgery’s razor-thin margin of error, how to predict the risk for brain tumours and the value of staying in the moment.

    Read the full interview in Best Health Canada magazine.

    This research was published in the high impact journal Nature Medicine (Open Access)

    Nassiri, F., Patil, V., Yefet, L.S. et al. Oncolytic DNX-2401 virotherapy plus pembrolizumab in recurrent glioblastoma: a phase 1/2 trial. Nat Med 29, 1370–1378 (2023). https://doi.org/10.1038/s41591-023-02347-y

    Visit the Zadeh lab website to learn more about her groundbreaking research.

    Dr. Gelareh Zadeh is one of this year’s recipients of the 2023 Canada Gairdner Momentum Awards.


  • Life-saving oxygen therapy administered to preterm infants often leads to a chronic lung disease called bronchopulmonary dysplasia (BPD). BPD is associated with abnormal neurodevelopment, such as motor and cognitive deficits, yet this association was previously not well understood. Marissa Lithopoulos, PhD student at the University of Ottawa, led a study that established a neonatal mouse model of hyperoxia-induced BPD. This was the first investigation to explore the long-term consequences on neural progenitor cells (NPCs, which are the cells that become neurons) and the surrounding blood vessels (the vascular niche), components crucial for neurodevelopment. Lithopoulos and colleagues found that neonatal hyperoxia exposure dysregulated vascular function and this was associated with significant long-term vascular remodeling. Further, they demonstrated that neonatal hyperoxia exposure led to a significant decline in the NPC population, NPC proliferation, and in neurogenesis in mice at postnatal day 14 and 1 year of age. The results found in mice were further confirmed utilizing NPCs from preterm neonatal baboons.

    Marissa Lithopoulos won a CAN-CIHR-INMHA Brain Star award for these discoveries.

    To better understand the mechanisms driving these deficits, the researchers conducted gene expression analysis of NPC niche brain regions. Neonatal hyperoxia exposure significantly altered the expression of genes crucial for new blood vessel growth (angiogenesis), vascular autoregulation, cell growth/genesis (proliferation), and new neuron formation (neurogenesis). These impairments correlated with motor and cognitive deficits in aging hyperoxia-exposed mice, similar to deficits observed in BPD patients.

    The potential impact of this research is significant to preterm infants and their families, as well as to the fields of neuroscience, neonatology, and developmental biology. Sadly, preterm birth affects 15 million infants worldwide annually. This study may considerably influence neonatology practices to utilize oxygen therapy in a judicious manner to improve outcomes for infants affected by preterm birth worldwide. Furthermore, this study links BPD with abnormal neurodevelopment, by uncovering the role of NPCs and their vascular niche. It therefore fills key gaps in our knowledge and provides new cellular therapeutic targets to explore in future research. Moreover, Lithopoulos and colleagues identified molecular mechanisms that may contribute to hyperoxia-induced impairments. The mechanisms highlighted in this research, as well as data the research group has shared publicly, can stimulate additional research to further our understanding of hyperoxia-induced brain injury and lead to the development of potential therapies to aid this vulnerable patient population. This research also demonstrates that early perturbations in brain development during the postnatal period can have life-long consequences. And, finally, the clinically pertinent baboon model used in the study can be used in the future to better understand neurodevelopmental disorders at unique gestational timepoints.

    About Dr. Marissa Lithopoulos

    Dr. Marissa Lithopoulos’ passion for improving the lives of preterm infants stems from losing her brother to preterm birth complications. Dr. Lithopoulos conducted this research as a PhD student in the laboratory of Dr. Bernard Thébaud at the Ottawa Hospital Research Institute, after obtaining a Canadian Institutes of Health Research (CIHR) Frederick Banting and Charles Best Canada Graduate Scholarship. As the project team lead, she conceptualized and designed the experiments in this study and acquired most of the data. This was a highly collaborative study and several researchers contributed intellectually. In instances that required the expertise of others, Dr. Lithopoulos sought out local neuroscience experts: Drs. Baptiste Lacoste, Jing Wang, Diane Lagace, and Ruth Slack. For neonatal baboon experiments, Dr. Lithopoulos facilitated an international collaboration with world renowned scientists and acquired a CIHR Michael Smith Foreign Study Supplement, to conduct experiments at the University of Texas at San Antonio, which houses the only preterm baboon model in the world. With guidance from Drs. Steven Seidner, Shamimunisa Mustafa, Alvaro Moreira, and Cynthia Blanco, she became the first scientist to isolate NPCs from preterm neonatal baboons, which helped strengthen the clinical relevance of this study. Dr. Lithopoulos interpreted the data with assistance from her supervisor and collaborators and wrote the research publication. Dr. Lithopoulos received her PhD in June 2021 and is now a Postdoctoral Fellow at the Hospital for Sick Children and a Visiting Scientist at The University of British Columbia working with prominent world leaders in the field of stem cell biology, Dr. David Kaplan and Dr. Freda Miller. Dr. Lithopoulos is supported by a CIHR Fellowship and continues her research to understand and improve preterm birth outcomes.

    Source of funding

    This study was supported by CIHR, the Stem Cell Network, the Ontario Institute for Regenerative Medicine, the Children’s Hospital of Eastern Ontario Foundation, and Fundação de Amparo à Pesquisa do Estado de São Paulo #2021/12354-8, #2018/09125-4.

    Scientific publication

    Lithopoulos MA, Toussay X, Zhong S, Xu L, Mustafa SB, Ouellette J, Freitas-Andrade M, Comin CH, Bassam HA, Baker AN, Sun Y, Wakem M, Moreira AG, Blanco CL, Vadivel A, Tsilfidis C, Seidner SR, Slack RS, Lagace DC, Wang J, Lacoste B, Thébaud B. Neonatal hyperoxia in mice triggers long-term cognitive deficits via impairments in cerebrovascular function and neurogenesis. Journal of Clinical Investigation. 2022;132(22):e146095.

    https://www.jci.org/articles/view/146095


  • SickKids researchers discover that a matrix called the perineuronal net may be responsible for why human memories become more specific throughout childhood.

    How do our brains become capable of creating specific memories? In one of the first preclinical studies to examine memory development in youth, a research team at The Hospital for Sick Children (SickKids) may have identified a molecular cause for memory changes in early childhood. (more…)


  • In a study published in Nature Communications, a team led by UHN Krembil Brain Institute Senior Scientists Drs. Lorraine Kalia and Suneil Kalia and University of Toronto (U of T) professor Dr. Philip M. Kim identified a protein-protein interaction that contributes to Parkinson’s disease.

    In the disease, a protein called α-synuclein (a-syn) accumulates in the brain and leads to cell death. Much research is currently focused on clearing a-syn with antibodies or using small molecules to prevent a-syn from aggregating.

    In this study, the researchers took an alternate approach by looking for protein-protein interactions that may be promoting the accumulation of a-syn. Through this approach, the team identified a peptide that reduced a-syn levels in cells 

    “We tested the peptide in multiple experimental models of Parkinson’s disease, and we consistently found that it restored endolysosomal function, promoted a-syn clearance and prevented cell death,” says Dr. Suneil Kalia, who is also an associate professor in the Division of Neurosurgery, Department of Surgery, and in the Department of Laboratory Medicine and Pathobiology at U of T, and is the R.R. Tasker Chair in Stereotactic and Functional Neurosurgery at UHN.

    Read the full story on the UHN Foundation website


  • “For advancing the molecular and genomic understanding of brain tumours, leading to better ways of discriminating, classifying and managing brain tumour subtypes with potential to transform the clinical care of the disease.

    Gairdner Foundation

    Congratulations to Dr. Gelareh Zadeh, MD, PhD, FRCS(C), FAANS, who is the Dan Family Chair and Professor of Neurosurgery, University of Toronto on winning a 2023 Canada Gairdner Momentum Award!

    Dr. Gelareh Zadeh is a neurosurgeon and senior scientist who combines her in-depth clinical knowledge of brain cancer with clinical and translational research to improve the diagnosis and management of adult brain tumours.

    Dr. Zadeh’s research program applies advanced genomic and epigenomic profiling to further our understanding of the molecular regulators of brain tumours and to develop tools that can refine biomarkers of diagnosis to predict treatment responses and ultimately, improve patient outcomes.

    Learn more about Dr. Zadeh’s work on the Gairdner award website: https://www.gairdner.org/winner/gelareh-zadeh

    [su_youtube_advanced url=”https://www.youtube.com/watch?v=maMytT8NjAw” rel=”no” modestbranding=”yes”]


  • A University of Toronto and Unity Health Toronto study found that listening to songs with special meaning for the listener improves brain function in patients with early Alzheimer’s disease or mild cognitive impairment, CNN reported.

    Senior author Michael Thaut, director of U of T’s Music and Health Science Research Collaboratory and a professor in the Faculty of Music and Temerty Faculty of Medicine, told the U.S. news outlet that “listening to music with special meaning stimulated neural pathways in the brain that helped them maintain higher levels of functioning.”

    “Whether you’re a lifelong musician or have never even played an instrument, music is an access key to your memory, your pre-frontal cortex,” said Thaut in a statement to CNN. “It’s simple — keep listening to the music that you’ve loved all your life. Your all-time favourite songs, those pieces that are especially meaningful to you – make that your brain gym.”

    The research – published in the Journal of Alzheimer’s Disease in November 2021 – could lead to promising music therapies for patients with early Alzheimer’s disease or mild cognitive impairment.

    Read more at CNN

    Read more at U of T News